A CLINICAL STUDY OF ORAL TE-031 (A-56268) IN RESPIRATORY INFECTIONS

We studied the clinical efficacy and safety of TE-031 (A-56268) in 13 patients with respiratory infection (pneumonia 4, acute bronchitis 4, bronchopneumonia 1, mycoplasma pneumonia 1, lung abscess 1, middle lobe syndrome 1, and exacer bated bronchiectasis 1), who were treated with oral TE-031 at a d...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 36; no. Supplement3; pp. 617 - 622
Main Authors KUDO, KOICHIRO, KABE, JUNZABURO, KOMASE, YUKO, KOWADA, AKIKO
Format Journal Article
LanguageEnglish
Japanese
Published Japanese Society of Chemotherapy 1988
公益社団法人 日本化学療法学会
Online AccessGet full text
ISSN0009-3165
1884-5894
DOI10.11250/chemotherapy1953.36.Supplement3_617

Cover

More Information
Summary:We studied the clinical efficacy and safety of TE-031 (A-56268) in 13 patients with respiratory infection (pneumonia 4, acute bronchitis 4, bronchopneumonia 1, mycoplasma pneumonia 1, lung abscess 1, middle lobe syndrome 1, and exacer bated bronchiectasis 1), who were treated with oral TE-031 at a daily dose of 200mg, 400mg or 600mg for 6-21 days. Overall clinical efficacy was 76.9%(10/13): good in 10 cases and fair in 3. No clinical side effect was observed. A slight increase in serum GPT level in one case was the only abnormal laboratory finding.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.36.Supplement3_617